secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001193125-23-024877
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics appoints Scott Myers as President and CEO, succeeding Jonathan Violin
--------------------------------------------------------------------------------

- Scott Myers, former CEO of AMAG Pharmaceuticals, appointed President & CEO and Class III Director effective Feb 6, 2023.
- Founding CEO Jonathan Violin steps down; receives 18-month salary severance, 12-month accelerated option vesting, and consulting role.
- Myers granted inducement award of 1,000,000 stock options and 250,000 RSUs, vesting over 4 years with first cliff at 12 months.
- Company references positive topline data from Phase 1/2 trial of VRDN-001 for thyroid eye disease (previously filed presentation).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/d406212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-024877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer